CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
了解 CAR-T 研究作为侵袭性淋巴瘤二线治疗时结果差异的原因
英文原题：Understanding the differences in outcome between CART studies as second-line treatment in aggressive lymphoma.
查看英文原题
Understanding the differences in outcome between CART studies as second-line treatment in aggressive lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
难治性/早期复发的侵袭性淋巴瘤患者属于血液肿瘤中最难治疗的患者群体。此类患者预后较差，迫切需要新的治疗方法。自体CAR-T 细胞疗法是一种有前景的新治疗选择，已在两线化疗失败后获得批准。最近，三项不同的CAR-T 研究（ZUMA-7、TRANSFORM和BELINDA）的结果已发表。其中两项为阳性，一项为阴性，这造成了失望、困惑和恼怒交织的局面。在本文中，我们分析了所有三项试验的数据，并阐明了各项研究之间的差异，这可能有助于更容易理解CAR-T 在侵袭性大B细胞淋巴瘤中的结果及其相关性。
展开英文摘要原文
Patients with refractory/early relapsed aggressive lymphomas belong to the most difficult-to-treat patients with hematological neoplasia. The prognosis of such patients is poor and novel treatment approches are urgently needed. Autologous chimeric antigen receptor T-cell therapy is a promising new therapy option that is approved after the failure of two lines of chemotherapy.
Recently, the results of three different CART studies (ZUMA-7, TRANSFORM, and BELINDA) were published. Two of them were positive and one was negative, which created a mix of disappointment, confusion, and irritation. In this article, we are analyzing the data of all three trials and shed light on the differences between the studies which may facilitate an easier understanding of the results and relevance of CART in aggressive large B-cell lymphoma.
论文信息
- 作者
- Dada R
- 单位
- Department of Oncology, King Faisal Specialist Hospital and Research Centre, Jeddah, Kingdom of Saudi Arabia.Saudi Arabia
- 文献类型
- 综述
- 期刊
- Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners2023 Jan
- 原文标识
- PubMed 35786102 · DOI 10.1177/10781552221110806